TY - JOUR
T1 - Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion
AU - Maehara, Yoshihiko
AU - Okuyama, Toshiro
AU - Kakeji, Yoshirio
AU - Baba, Hideo
AU - Furusawa, Motonosuke
AU - Sugimachi, Keizo
PY - 1994/7
Y1 - 1994/7
N2 - The effects of postoperative immunochemotherapy including the streptococcal preparation OK-432 on the rate of peritoneal recurrence and survival time after curative resection were studied in 36 patients with gastric cancer. Patients randomized to group B received 18 months of a therapy that is widely used in Japan for patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4. Patients randomized to group A received the same drugs given to group B plus an intraperitoneal injection of OK-432 on postoperative day 0 and intradermal injections of OK-432 for 18 months at 2-week intervals. There were no differences between the two groups in any known prognostic factor or dose of any drug received, except for OK-432. There was no difference in the toxicity rates between the groups. The concomitant administration OK-432 and anticancer drugs significantly decreased the rates of peritoneal recurrence and lengthened survival time (P <0.05).
AB - The effects of postoperative immunochemotherapy including the streptococcal preparation OK-432 on the rate of peritoneal recurrence and survival time after curative resection were studied in 36 patients with gastric cancer. Patients randomized to group B received 18 months of a therapy that is widely used in Japan for patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4. Patients randomized to group A received the same drugs given to group B plus an intraperitoneal injection of OK-432 on postoperative day 0 and intradermal injections of OK-432 for 18 months at 2-week intervals. There were no differences between the two groups in any known prognostic factor or dose of any drug received, except for OK-432. There was no difference in the toxicity rates between the groups. The concomitant administration OK-432 and anticancer drugs significantly decreased the rates of peritoneal recurrence and lengthened survival time (P <0.05).
UR - http://www.scopus.com/inward/record.url?scp=0028153407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028153407&partnerID=8YFLogxK
U2 - 10.1016/S0002-9610(05)80068-6
DO - 10.1016/S0002-9610(05)80068-6
M3 - Article
C2 - 8024097
AN - SCOPUS:0028153407
VL - 168
SP - 36
EP - 40
JO - American Journal of Surgery
JF - American Journal of Surgery
SN - 0002-9610
IS - 1
ER -